BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nowakowski GS, Zhu J, Zhang Q, Brody J, Sun X, Maly J, Song Y, Rizvi S, Song Y, Lansigan F, Jing H, Cao J, Lue JK, Luo W, Zhang L, Li L, Han I, Sun J, Jivani M, Liu Y, Heineman T, Smith SD. ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. Future Oncol 2020;16:991-9. [PMID: 32250167 DOI: 10.2217/fon-2020-0176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Khurana A, Mwangi R, Nowakowski GS, Habermann TM, Ansell SM, LaPlant BR, Link BK, Cerhan JR, Maurer MJ, Witzig TE. Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? J Clin Oncol 2021;39:1641-9. [PMID: 33529046 DOI: 10.1200/JCO.20.01935] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Lue JK, O'Connor OA. A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise. Lancet Haematol 2020;7:e838-50. [PMID: 33091357 DOI: 10.1016/S2352-3026(20)30222-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol 2020;13:175. [PMID: 33317571 DOI: 10.1186/s13045-020-01011-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 He MY, Kridel R. Treatment resistance in diffuse large B-cell lymphoma. Leukemia 2021;35:2151-65. [PMID: 34017074 DOI: 10.1038/s41375-021-01285-3] [Reference Citation Analysis]
5 Cherng HJ, Westin J. Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma. Leuk Lymphoma 2021;62:1302-12. [PMID: 33403905 DOI: 10.1080/10428194.2020.1869228] [Reference Citation Analysis]